Abstract
Purpose :
To evaluate the accuracy of MultiColor imaging (MC) compared to fluorescein angiography (FA) in detecting proliferative diabetic retinopathy (PDR) and associated diabetic retinopathy features.
Methods :
Fifty-nine eyes from 38 PDR patients were included. MC images were reviewed by 2 independent masked graders. A qualitative analysis based on the following features was performed: neovascular complexes (NVC), disc neovascularization (NVD), neovascularization elsewhere (NVE), microaneurysm (MA), intraretinal hemorrhage (IRH), vitreous hemorrhage (VH), preretinal hemorrhage (PRH), fibrosis, hard exudates (HE), epiretinal membrane (ERM), diabetic macular edema (DME), ischemia and laser spots (LS). Measures of diagnostic accuracy compared to FA were determined.
Results :
The sensitivity for the detection of NVC using MC was 95.1%, with a specificity of 40.0%, positive predictive value (PPV) of 92.9% and negative predictive value (NPV) of 50.0%. Sensitivity and specificity were higher in detecting NVD (88.9% and 76.9%) while NVE registered higher PPV (88.9%). MC was highly sensitive in detecting IRH, HE, ERM and LS (100%), MA (98.0%) and fibrosis (95.5%). Highest specificity was found for VH (100.0%), DME (100.0%), PRH (98.1%) and LS (89.5%). The area under the receiver-operating characteristic analysis of MC was excellent in NVD (0.83, 95% confidence interval (CI), 0.71-0.95, p<0.001), IRH (0.89, 95% CI 0.74-1.00, p<0.001), VH (0.81, 95% CI 0.60-1.00, p=0.005) and PRH (0.89, 95% CI 0.68-1.00, p=0.004) and outstanding in LS detection (0.95, 95% CI 0.87-1.00, p<0.001). These results are likely due to the contrast and quality of the MC, since a better discrimination is enabled by the green wavelength. The intergrader agreement for the MC features accessed was almost perfect with a weighted kappa of 0.86 (standard error: 0.02, 95% confidence interval: 0.82–0.88).
Conclusions :
MC detected some PDR features such as NVD, VH, PRH, IRH and laser spots, more accurately than FA. These findings make MC a useful test for the diagnosis and follow-up evaluation of PDR, complementing the noninvasive imaging of this disease.
This is a 2021 ARVO Annual Meeting abstract.